UBS O'Connor’s Aclaris Therapeutics ACRS Stock Holding History

UBS O'Connor’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-70,000	Closed	-$117K	–	506
2023 Q3	$117K	Buy	+70,000	New	+$598K	﹤0.01%	460

Other funds holding ACRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

UBS O'Connor's ACRS Position: Q4 2023 in Review

UBS O'Connor sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 68,014 shares — an estimated $466K sold.

UBS O'Connor first reported a position in ACRS in Q2 2022 and held it in 5 quarters. The position peaked at $1.78M in Q3 2022. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

UBS O'Connor reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
UBS O'Connor sold 68,014 Aclaris Therapeutics shares in Q4 2023, an estimated $466K.
UBS O'Connor first reported a position in Aclaris Therapeutics in Q2 2022 and held it in 5 quarters.
UBS O'Connor's Aclaris Therapeutics position peaked at $1.78M in Q3 2022.
107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.